Form 8-K

8-K — Sunshine Biopharma Inc.

Accession: 0001683168-26-002781

Filed: 2026-04-09

Period: 2026-04-06

CIK: 0001402328

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — sunshine_8k.htm (Primary)

EX-99.1 — PRESS RELEASE (sunshine_ex9901.htm)

GRAPHIC (image_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: sunshine_8k.htm · Sequence: 1

8-K

false

0001402328

2026-04-06

0001402328

us-gaap:CommonStockMember

2026-04-06

0001402328

SBFM:CommonStockPurchaseWarrantsMember

2026-04-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM

8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported): April

6, 2026

SUNSHINE

BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Colorado

001-41282

20-5566275

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer ID No.)

333

Las Olas Way

CU4

Suite 433

Fort Lauderdale, FL 33301

(Address of principal executive offices) (zip

code)

(954) 330-0684

(Registrant’s telephone number, including area code)

Securities

registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.001

SBFM

The Nasdaq

Stock Market LLC

Common Stock Purchase Warrants

SBFMW

The Nasdaq

Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial

Condition.

On April 6, 2026, Sunshine Biopharma Inc.

(the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31,

2025. The press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of

Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to

the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under

the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

Exhibit No.

Description

99.1

Press Release

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Dated: April 9, 2026

SUNSHINE BIOPHARMA INC.

By: /s/ Dr. Steve N. Slilaty

Dr. Steve N. Slilaty, Chief Executive Officer

EX-99.1 — PRESS RELEASE

EX-99.1

Filename: sunshine_ex9901.htm · Sequence: 2

Exhibit 99.1

Sunshine

Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

FORT LAUDERDALE, FL / ACCESSWIRE

/ April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) (“Sunshine Biopharma” or the “Company”), a pharmaceutical

company offering and developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the

filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

2025

Highlights

· Revenue of $36.3 million, representing a 4.1% increase compared to 2024.

· $2.46 million in gross proceeds raised through a registered direct offering to

support expansion of sales operations.

· Nine new generic prescription drugs launched, expanding the Company’s portfolio

in oncology, cardiovascular health, central nervous system disorders, and antimicrobials.

· Advancement of proprietary antiviral research, including a new series of orally

active, non-covalent PLpro protease inhibitors that demonstrated dose-dependent antiviral activity in SARS-CoV-2-infected mice, strong

potency in cellular models, and favorable pharmacokinetics.

Management

Commentary

“We are pleased with our

accomplishments in 2025, as we remain committed to reaching profitability in the near future,” said Dr. Steve Slilaty, CEO. “Looking

ahead, we are excited about the opportunities for growth in 2026 and beyond as we continue expanding our generic drug portfolio and advancing

our proprietary drug development programs to deliver more life-saving medicines to the market.”

Financial Summary (in millions)

2025

2024

Revenue

$ 36.31

$ 34.87

Gross Profit

$ 12.26

$ 10.67

General & Administrative Expenses

$ 18.48

$ 16.48

Net Loss

$ 5.98

$ 5.13

The increase in General &

Administrative Expenses in 2025 was primarily driven by a non-cash, non-recurring impairment charge of $1.75 million related to intangible

assets. Excluding this charge, the Company’s operating performance reflects a meaningful improvement over 2024.

In January

2026, Sunshine Biopharma implemented cost-reduction initiatives aimed at lowering general and administrative expenses and sharpening

the Company’s focus on achieving near-term profitability. Based on current plans, these initiatives are expected to reduce expenses

by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized.

About

Sunshine Biopharma

Sunshine Biopharma currently markets

71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing

two proprietary drug development programs:

· K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer.

· PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related

coronavirus infections.

Additional information is available

at www.sunshinebiopharma.com.

Forward-Looking

Statements

This press release contains forward-looking

statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties. These statements include, but

are not limited to, those regarding the Company’s financial performance, drug development activities, and future growth opportunities.

Actual results may differ materially due to various risks and uncertainties described in the Company’s filings with the U.S. Securities

and Exchange Commission. Readers are encouraged to review the Company’s most recent SEC filings for additional information.

Contact:

Camille Sebaaly, CFO

Direct Line:

514-814-0464

camille.sebaaly@sunshinebiopharma.com

GRAPHIC

Filename: image_001.jpg · Sequence: 7

Binary file (5889 bytes)

Download image_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Apr. 06, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 06, 2026

Entity File Number

001-41282

Entity Registrant Name

SUNSHINE

BIOPHARMA INC.

Entity Central Index Key

0001402328

Entity Tax Identification Number

20-5566275

Entity Incorporation, State or Country Code

Entity Address, Address Line One

333

Las Olas Way

Entity Address, Address Line Two

CU4

Suite 433

Entity Address, City or Town

Fort Lauderdale

Entity Address, State or Province

Entity Address, Postal Zip Code

33301

City Area Code

(954)

Local Phone Number

330-0684

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock [Member]

Title of 12(b) Security

Common Stock, par value $0.001

Trading Symbol

SBFM

Security Exchange Name

NASDAQ

Common Stock Purchase Warrants [Member]

Title of 12(b) Security

Common Stock Purchase Warrants

Trading Symbol

SBFMW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=SBFM_CommonStockPurchaseWarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: